Retraction: Gastrin-releasing peptide blockade as a broad-spectrum anti-inflammatory therapy for asthma (Proceedings National Academy Sciences USA (2011) 108 (2100-2105) DOI: 10.1073/pnas.1014792108);Gastrin-releasing peptide blockade as a broadspectrum anti-inflammatory therapy for asthma

Proceedings of the National Academy of Sciences of the United States of America

Volumn 108, Issue 5, 2011, Pages 2100-2105

  Zhou, Shutang ^a   Potts, Erin N ^a   Cuttitta, Frank ^b   Foster, W Michael ^a   Sunday, Mary E ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Bombesin; Gastrin releasing peptide receptor phosphorylation; Mouse models

Indexed keywords

CYTOKINE; DEXAMETHASONE; GASTRIN ANTAGONIST; GASTRIN RELEASING PEPTIDE RECEPTOR; OVALBUMIN; SERINE;

AIR POLLUTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTHMA; FEMALE; GRANULOCYTE; LUNG LAVAGE; MACROPHAGE; MOUSE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN PHOSPHORYLATION; RECEPTOR BLOCKING; RESPIRATORY TRACT ALLERGY; T LYMPHOCYTE;

MURINAE; MUS;

EID: 79952145156     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1504672112     Document Type: Erratum

References (58)

1. Cotran RS, Kumar V, Collins T (1999) Robbins' Pathologic Basis of Disease (Saunders, Philadelphia), 6th Ed.
2. Kim HY, DeKruyff RH, Umetsu DT (2010) The many paths to asthma: Phenotype shaped by innate and adaptive immunity. Nat Immunol 11:577-584.
3. Beasley R (2002) The burden of asthma with specific reference to the United States. J Allergy Clin Immunol 109(5 Suppl):S482-S489.
4. Gaga M, et al., ENFUMOSA Study Group (2005) Risk factors and characteristics associated with severe and difficult to treat asthma phenotype: An analysis of the ENFUMOSA group of patients based on the ECRHS questionnaire. Clin Exp Allergy 35:954-959. (Pubitemid 41032546)
5. Shore SA, Drazen JM (2003) Beta-agonists and asthma: Too much of a good thing? J Clin Invest 112:495-497.
6. Sunday ME, Yoder BA, Cuttitta F, Haley KJ, Emanuel RL (1998) Bombesin-like peptide mediates lung injury in a baboon model of bronchopulmonary dysplasia. J Clin Invest 102:584-594. (Pubitemid 28376161)
7. Ng DK, Lau WY, Lee SL (2000) Pulmonary sequelae in long-term survivors of bronchopulmonary dysplasia. Pediatr Int 42:603-607. (Pubitemid 32039396)
8. Evans M, Palta M, Sadek M, Weinstein MR, Peters ME (1998) Associations between family history of asthma, bronchopulmonary dysplasia, and childhood asthma in very low birth weight children. Am J Epidemiol 148:460-466. (Pubitemid 28411103)
9. Bai TR, Knight DA (2005) Structural changes in the airways in asthma: Observations and consequences. Clin Sci (Lond) 108:463-477. (Pubitemid 40827554)
10. Hamid Q, Tulic' MK, Liu MC, Moqbel R (2003) Inflammatory cells in asthma: Mechanisms and implications for therapy. J Allergy Clin Immunol, 111(1 Suppl): S5-S12, discussion S12-S17.
11. Lilly CM (2005) Diversity of asthma: Evolving concepts of pathophysiology and lessons from genetics. J Allergy Clin Immunol 115(4 Suppl):S526-S531.
12. Groneberg DA, Quarcoo D, Frossard N, Fischer A (2004) Neurogenic mechanisms in bronchial inflammatory diseases. Allergy 59:1139-1152. (Pubitemid 39389466)
13. Joos GF, Germonpre PR, Kips JC, Peleman RA, Pauwels RA(1994) Sensory neuropeptides and the human lower airways: Present state and future directions. Eur Respir J 7:1161-1171. (Pubitemid 24187338)
14. Chanez P, et al. (1998) Bronchial mucosal immunoreactivity of sensory neuropeptides in severe airway diseases. Am J Respir Crit Care Med 158:985-990. (Pubitemid 28449470)
15. Dusser DJ, Djokic TD, Borson DB, Nadel JA (1989) Cigarette smoke induces bronchoconstrictor hyperresponsiveness to substance P and inactivates airway neutral endopeptidase in the guinea pig. Possible role of free radicals. J Clin Invest 84:900-906. (Pubitemid 19228362)
16. Linnoila RI (2006) Functional facets of the pulmonary neuroendocrine system. Lab Invest 86:425-444.
17. Wharton J, et al. (1978) Bombesin-like immunoreactivity in the lung. Nature 273:769-770. (Pubitemid 8357095)
18. Sunday ME, Hua J, Dai HB, Nusrat A, Torday JS (1990) Bombesin increases fetal lung growthandmaturationinuteroandinorganculture.AmJ Respir CellMol Biol 3:199-205.
19. King KA, Torday JS, Sunday ME (1995) Bombesin and [Leu8]phyllolitorin promote fetal mouse lung branching morphogenesis via a receptor-mediated mechanism. Proc Natl Acad Sci USA 92:4357-4361.
20. Subramaniam M, et al. (2007) Bombesin-like peptides modulate alveolarization and angiogenesis in bronchopulmonary dysplasia. Am J Respir Crit Care Med 176:902-912. (Pubitemid 350097080)
21. Impicciatore M, Bertaccini G (1973) The bronchoconstrictor action of the tetradecapeptide bombesin in the guinea-pig. J Pharm Pharmacol 25:872-875.
22. Lach E, Haddad EB, Gies JP (1993) Contractile effect of bombesin on guinea pig lung in vitro: Involvement of gastrin-releasing peptide-preferring receptors. Am J Physiol 264:L80-L86. (Pubitemid 23056739)
23. Bousbaa H, Fleury-Feith J (1991) Effects of a long-standing challenge on pulmonary neuroendocrine cells of actively sensitized guinea pigs. Am Rev Respir Dis 144:714-717.
24. Aguayo SM, et al. (1992) Brief report: Idiopathic diffuse hyperplasia of pulmonary neuroendocrine cells and airways disease. N Engl J Med 327:1285-1288.
25. Deterding RR, Pye C, Fan LL, Langston C (2005) Persistent tachypnea of infancy is associated with neuroendocrine cell hyperplasia. Pediatr Pulmonol 40:157-165. (Pubitemid 41099432)
26. Cullen A, et al. (2002) Urine bombesin-like peptide elevation precedes clinical evidence of bronchopulmonary dysplasia. Am J Respir Crit Care Med 165:1093-1097. (Pubitemid 34415816)
27. Subramaniam M, et al. (2003) Bombesin-like peptides and mast cell responses: Relevance to bronchopulmonary dysplasia? Am J Respir Crit Care Med 168:601-611.
28. Rosen DM, et al. (2006) Accelerated thymic maturation and autoreactive T cells in bronchopulmonary dysplasia. Am J Respir Crit Care Med 174:75-83.
29. Del Rio M, De la Fuente M (1994) Chemoattractrant capacity of bombesin, gastrin-releasing peptide and neuromedin C is mediated through PKC activation in murine peritoneal leucocytes. Peptides 49:185-193. (Pubitemid 24035009)
30. Yule KA, White SR (1999) Migration of 3T3 and lung fibroblasts in response to calcitonin gene-related peptide and bombesin. Exp Lung Res 25:261-273. (Pubitemid 29210663)
31. Rozengurt E, Sinnett-Smith J (1990) Bombesin stimulation of fibroblast mitogenesis: Specific receptors, signal transduction and early events. Philos Trans R Soc Lond B Biol Sci 327:209-221.
32. Cullen A, et al. (2000) Bombesin-like peptide (BLP) and BLP receptors in two different baboon models of bronchopulmonary dysplasia: Diversity in gene expression yet similarity in function. Peptides 21:1627-1638.
33. Dozor AJ (2010) The role of oxidative stress in the pathogenesis and treatment of asthma. Ann N Y Acad Sci 1203:133-137.
34. Savov JD, et al. (2004) Ozone-induced acute pulmonary injury in inbred mouse strains. Am J Respir Cell Mol Biol 31:69-77. (Pubitemid 38888041)
35. Whitehead GS, Walker JK, Berman KG, Foster WM, Schwartz DA (2003) Allergen-induced airway disease is mouse strain dependent. Am J Physiol Lung Cell Mol Physiol 285:L32-L42. (Pubitemid 36736466)
36. Shriver SP, et al. (2000) Sex-specific expression of gastrin-releasing peptide receptor: Relationship to smoking history and risk of lung cancer. J Natl Cancer Inst 92:24-33. (Pubitemid 30082225)
37. Hollingsworth JW, et al. (2007) Ambient ozone primes pulmonary innate immunity in mice. J Immunol 179:4367-4375.
38. Williams AS, et al. (2008) Role of p38 mitogen-activated protein kinase in ozone-induced airway hyperresponsiveness and inflammation. Eur J Pharmacol 600:117-122.
39. Voynow JA, et al. (2009) NAD(P)H quinone oxidoreductase 1 is essential for ozone-induced oxidative stress in mice and humans. Am J Respir Cell Mol Biol 41:107-113.
40. Baxter LT, Zhu H, Mackensen DG, Jain RK (1994) Physiologically based pharmacokinetic model for specific and nonspecific monoclonal antibodies and fragments in normal tissues and human tumor xenografts in nude mice. Cancer Res 54:1517-1528. (Pubitemid 24106416)
41. Martínez A, Zudaire E, Julián M, Moody TW, Cuttitta F (2005) Gastrin-releasing peptide (GRP) induces angiogenesis and the specific GRP blocker 77427 inhibits tumor growth in vitro and in vivo. Oncogene 24:4106-4113.
42. Corjay MH, et al. (1991) Two distinct bombesin receptor subtypes are expressed and functional in human lung carcinoma cells. J Biol Chem 266:18771-18779. (Pubitemid 21908150)
43. Williams BY, Wang Y, Schonbrunn A (1996) Agonist binding and protein kinase C activation stimulate phosphorylation of the gastrin-releasing peptide receptor at distinct sites. Mol Pharmacol 50:716-727. (Pubitemid 26347690)
44. Chang LY, et al. (2003) A catalytic antioxidant attenuates alveolar structural remodeling in bronchopulmonary dysplasia. Am J Respir Crit Care Med 167:57-64.
45. Ally RA, et al. (2003) Agonist- and protein kinase C-induced phosphorylation have similar functional consequences for gastrin-releasing peptide receptor signaling via Gq. Mol Pharmacol 64:890-904. (Pubitemid 37153058)
46. De la Fuente M, Del Rio M, Ferrandez MD, Hernanz A (1991) Modulation of phagocytic function in murine peritoneal macrophages by bombesin, gastrin-releasing peptide and neuromedin C. Immunology 73:205-211.
47. Lemaire I (1991) Bombesin-related peptides modulate interleukin-1 production by alveolar macrophages. Neuropeptides 20:217-223.
48. Meloni F, et al. (1996) Bombesin enhances monocyte and macrophage activities: Possible role in the modulation of local pulmonary defenses in chronic bronchitis. Respiration 63:28-34. (Pubitemid 26039584)
49. Csillag A, et al. (2010) Pollen-induced oxidative stress influences both innate and adaptive immune responses via altering dendritic cell functions. J Immunol 184:2377-2385.
50. Polak JM, et al. (1993) Lung endocrine cell markers, peptides, and amines. Anat Rec 236:169-171. (Pubitemid 23148406)
51. Levine SJ, Wenzel SE (2010) Narrative review: The role of Th2 immune pathway modulation in the treatment of severe asthma and its phenotypes. Ann Intern Med 152:232-237.
52. DeMichele MA, Davis AL, Hunt JD, Landreneau RJ, Siegfried JM (1994) Expression of mRNA for three bombesin receptor subtypes in human bronchial epithelial cells. Am J Respir Cell Mol Biol 11:66-74.
53. Finkelman FD, Hogan SP, Hershey GK, Rothenberg ME, Wills-KarpM(2010) Importance of cytokines in murine allergic airway disease and human asthma. J Immunol 184:1663-1674.
54. Dahl R (2006) Systemic side effects of inhaled corticosteroids in patients with asthma. Respir Med 100:1307-1317.
55. Chaudhry A, et al. (1999) Phase I and imaging trial of a monoclonal antibody directed against gastrin-releasing peptide in patients with lung cancer. Clin Cancer Res 5:3385-3393.
56. Kelley MJ, et al. (1997) Antitumor activity of a monoclonal antibody directed against gastrin-releasing peptide in patients with small cell lung cancer. Chest 112:256-261. (Pubitemid 27343628)
57. Fischer JR, et al. (1997) Decrease of interleukin-2 secretion is a new independent prognostic factor associated with poor survival in patients with small-cell lung cancer. Ann Oncol 8:457-461. (Pubitemid 27310690)
58. Van Lommel A, Bollé T, Fannes W, Lauweryns JM (1999) The pulmonary neuroendocrine system: The past decade. Arch Histol Cytol 62:1-16. (Pubitemid 29197734)